Office of the WHO-Representative in India, World Health Organization (WHO), New Delhi, India.
PLoS One. 2012;7(7):e39040. doi: 10.1371/journal.pone.0039040. Epub 2012 Jul 9.
Excessive time between diagnosis and initiation of tuberculosis (TB) treatment contributes to ongoing TB transmission and should be minimized. In India, Revised National TB Control Programme (RNTCP) focuses on indicator start of treatment within 7 days of diagnosis for patients with sputum smear-positive PTB for monitoring DOTS implementation.
To determine length of time between diagnosis and initiation of treatment and factors associated with delays of more than 7 days in smear-positive pulmonary TB.
Using existing programme records such as the TB Register, treatment cards, and the laboratory register, we conducted a retrospective cohort study of all patients with smear-positive pulmonary TB registered from July-September 2010 in two districts in India. A random sample of patients with pulmonary TB who experienced treatment delay of more than 7 days was interviewed using structured questionnaire.
2027 of 3411 patients registered with pulmonary TB were smear-positive. 711(35%) patients had >7 days between diagnosis and treatment and 262(13%) had delays >15 days. Mean duration between TB diagnosis and treatment initiation was 8 days (range = 0-128 days). Odds of treatment delay >7 days was 1.8 times more likely among those who had been previously treated (95% confidence interval [CI] 1.5-2.3) and 1.6 (95% CI 1.3-1.8) times more likely among those diagnosed in health facilities without microscopy centers. The main factors associated with a delay >7 days were: patient reluctance to start a re-treatment regimen, patients seeking second opinions, delay in transportation of drugs to the DOT centers and delay in initial home visits. To conclude, treatment delay >7 days was associated with a number of factors that included history of previous treatment and absence of TB diagnostic services in the local health facility. Decentralized diagnostic facilities and improved referral procedures may reduce such treatment delays.
从诊断到开始结核病(TB)治疗之间的时间过长会导致持续的 TB 传播,应尽量缩短这一时间。在印度,修订后的国家结核病控制规划(RNTCP)侧重于在痰涂片阳性的肺结核患者中,在诊断后 7 天内开始治疗,以监测 DOTS 的实施情况。
确定从诊断到开始治疗之间的时间长度以及与痰涂片阳性肺结核患者超过 7 天的延迟相关的因素。
使用现有的方案记录,如结核登记簿、治疗卡和实验室登记簿,我们对 2010 年 7 月至 9 月期间在印度两个地区登记的所有痰涂片阳性肺结核患者进行了回顾性队列研究。对经历超过 7 天治疗延迟的肺结核患者进行了随机抽样,并使用结构化问卷进行了访谈。
在登记的 3411 例肺结核患者中,有 2027 例为痰涂片阳性。711 例(35%)患者在诊断和治疗之间的时间超过 7 天,262 例(13%)患者的延迟时间超过 15 天。从 TB 诊断到开始治疗的平均时间为 8 天(范围 0-128 天)。曾接受过治疗的患者发生治疗延迟>7 天的可能性是未接受过治疗的患者的 1.8 倍(95%置信区间 [CI] 1.5-2.3),在没有显微镜中心的医疗机构中诊断出的患者发生治疗延迟>7 天的可能性是未接受过治疗的患者的 1.6 倍(95% CI 1.3-1.8)。与治疗延迟>7 天相关的主要因素包括:患者不愿意开始重新治疗方案、患者寻求第二意见、药物运输到 DOTS 中心的延迟以及初始家访的延迟。总之,治疗延迟>7 天与包括既往治疗史和当地卫生机构缺乏结核病诊断服务在内的许多因素有关。分散诊断设施和改进转诊程序可能会减少这种治疗延迟。